In adults with obesity and prediabetes, weight loss achieved with tirzepatide was sustained at more than 3 years, according ...

Tirzepatide and semaglutide are type 2 diabetes drugs often used for weight loss. Tirzepatide is less expensive and may be more effective. However, the drug is still new, and more research is ...

Two drugs—tirzepatide and semaglutide—have shown striking results in helping people lose weight and keep it off. But until now, no one had directly compared their performance in people without ...

Both medications were effective: The vast majority of people using either tirzepatide or semaglutide lost at least 5% of their starting body weight after one year of use. But 82% of people taking ...

In real-world cohort, percentage weight reduction at 1 year was 3.6%, 6.8%, and 11.9% with early and late discontinuation and nondiscontinuation, respectively.

In the first head-to-head trial of its kind, people with obesity who took tirzepatide (sold under the brand names Mounjaro and Zepbound) lost more weight and inches from their waist than those ...

Each participant received weekly doses of tirzepatide—either 5 mg, 10 mg, or 15 mg—for three years. At the end of this period, the results were impressive. On average, participants lost ...

The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published, examining their ability to reduce weight and waist circumference.

Compounded tirzepatide contains the same active ingredient as Mounjaro, but its dosage and some ingredients may differ from Mounjaro. The Food and Drug Administration (FDA) does not regulate the ...

Get Instant Summarized Text (Gist) Tirzepatide significantly reduces calorie intake and increases fat oxidation, leading to greater weight loss in people with obesity compared to placebo. However ...

INDIANAPOLIS — Eli Lilly filed lawsuits against compounding pharmacies and an Indianapolis weight loss company over the use of Zepbound and Mounjaro. On April 1, 2025, Lilly filed lawsuits against two ...